TRAILBLAZER-ALZ 2

2 Posts

Key Findings From the TRAILBLAZER-ALZ 2 Study

The TRAILBLAZER-ALZ 2 study (NCT04437511) demonstrated significant clinical benefits of donanemab-azbt in early symptomatic Alzheimer disease (AD). Here are the key findings:Efficacy OutcomesCognitive & Functional....

Kisunla (Donanemab-azbt) Drug Info

Drug Information